Boundless Bio today announced that its President and Chief Executive Officer, Zachary Hornby, will present at the Stifel 2023 Virtual Targeted Oncology Days event which will take place virtually.
SAN DIEGO--(BUSINESS WIRE)-- Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its President and Chief Executive Officer, Zachary Hornby, will present at the Stifel 2023 Virtual Targeted Oncology Days event which will take place virtually. Presentation details are as follows:
Date: Tuesday, April 25, 2023
Time: 3:30 – 3:55 PM ET
About Boundless Bio
Boundless Bio is a next-generation precision oncology company dedicated to the discovery and development of new drugs targeting a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with oncogene amplified cancers.
For more information, visit www.boundlessbio.com.
Follow us on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230411005177/en/
Source: Boundless Bio
View this news release online at:
http://www.businesswire.com/news/home/20230411005177/en
